Barber Daniel 4

What Happened

• Daniel Barber, President and CEO of Aquestive Therapeutics (AQST), sold 180,677 shares in an open-market transaction on March 10, 2026 for total proceeds of $753,965 (weighted-average price $4.17). On March 9, 2026 he also received (a) 262,000 restricted shares (reported at $0) and (b) a derivative award covering 523,000 shares with a reported value of $4.29 per share (total $2,243,670). The sale was a routine “sell to cover” tied to tax withholding for vested awards, not a discretionary trade.

Key Details

• Transaction dates and prices:
  • Mar 9, 2026: Award of 262,000 restricted shares (reported $0) and derivative award for 523,000 shares at $4.29 ($2,243,670).
  • Mar 10, 2026: Open-market sale of 180,677 shares; weighted-average sale price $4.17 (individual trades ranged $4.17–$4.33).
• Shares owned after transaction: Not specified in the reported data on this filing.
• Notable footnotes:
  • F1/F4: Restricted stock and the options/derivative award vest in three annual installments (25% / 25% / 50%).
  • F2: The sale represents shares sold to satisfy tax-withholding obligations (a mandatory "sell to cover"), not a discretionary sale by the insider.
  • F3: Sale executed in multiple trades; weighted-average price reported.
• Filing timeliness: Form 4 was filed Mar 11, 2026 for transactions on Mar 9–10, 2026 (appears to be filed within the standard 2-business-day window).

Context

• The derivative award appears to be stock options or similar equity awards that vest over time; these are not immediate purchases of common stock and typically become meaningful only as they vest/exercised. The share sale was tied to tax withholding for vested awards (routine) rather than an independent investment decision.